Baricitinib shows encouraging phase III results in RA

SAN FRANCISCO – Baricitinib, an investigational oral investigational JAK 1/2 inhibitor, was significantly superior to adalimumab and to placebo in the treatment of patients with active rheumatoid...

Field of Interest: Rheumatology